Furthermore, pemvidutide is currently undergoing Phase II studies for various Metabolic Syndrome Hybrid Disorders (MASH)
Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, De Mouzon SH, Amini SB
Multiple cardiovascular outcomes trials (CVOTs) have shown significant reductions in major adverse cardiovascular events (MACE), which typically includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
Meeting protein needs through whole foods alone can feel challenging, particularly early in [GLP-1] treatment, she says, adding: Many people experience early fullness, nausea, or food aversions, making larger portions or solid protein foods less appealing. This is where meal- and snack-time strategies, as well as protein supplements, can be genuinely useful for filling nutritional gaps
The patches are said to be less effective at delivering GLP-1 agonist drugs, as they are large molecules
CT-996 was designed to exhibit signalling bias on the GLP-1 receptor, resulting in activation of cAMP with minimal to no recruitment of -arrestin